GB104 / GI Biome - LARVOL DELTA

Alleviation of Adipose Tissue Inflammation and Obesity Suppression by a Probiotic Strain That Induces GLP-1 Secretion. (PubMed, Microorganisms) - "In white adipose tissue, GB104 suppressed inflammation by reducing pro-inflammatory M1 macrophages and increasing anti-inflammatory M2 macrophages and regulatory T cells. Probiotic strains that promote GLP-1 secretion, such as GB104, may serve as a promising candidate for dietary intervention against obesity and metabolic diseases."

Journal • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • GCG • PCSK1

GB-X01-101: Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: GI Biome, Inc. | Recruiting ➔ Completed | N=18 ➔ 9

Enrollment change • Trial completion • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

First-in-human evaluation of the safety, tolerability, and gut microbial composition of a live biotherapeutic product GB104 in patients with colorectal cancer (SITC 2024) - P1 | "Ethics Approval GB104 was conducted in full accordance with Good Clinical Practice guidelines and the Declaration of Helsinki or the laws and regulations of the country in which the research was conducted, whichever afforded the most protection. Written informed consent was obtained from all the patients."

Clinical • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: GI Biome, Inc.

New P1 trial • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor